Lasmiditan Dosage

Medically reviewed by Drugs.com. Last updated on Sep 30, 2022.

Usual Adult Dose for Migraine

Initial dose: 50 mg, 100 mg, or 200 mg orally once
Maximum dose: 1 dose per day

Comments:

• This drug should not be taken unless the patient can wait 8 hours or more before driving or operating machinery.
• No more than 1 dose should be taken in 24 hours; a second dose has not been shown to be effective for the same migraine attack.
• The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.
• This drug is not indicated for the prevention of migraine attacks.

Use: For the acute treatment of migraine with or without aura.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild to moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: Not recommended

Dose Adjustments

Elderly: Dose selection should be cautious, generally starting at the low end of the dosing range

Precautions

CONTRAINDICATIONS:

• None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

US Controlled Substance: Schedule V

Dialysis

Data not available

Other Comments

Administration advice:

• Take orally with or without food; swallow tablets whole, do not split, crush, or chew
• Do not take more than 1 dose in a 24 hour period; the safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established
• Patients should wait at least 8 hours after dosing before driving or operating machinery

General:

• In a human abuse potential study, this drug showed statistically significantly higher "drug liking" scores than placebo and statistically significantly lower scores compared to alprazolam 2 mg; euphoric mood occurred to a similar extent with lasmiditan doses of 200 mg and 400 mg and alprazolam 2 mg (43% to 49%).
• Concomitant use with other CNS depressant drugs has not been evaluated in clinical studies.
• Patients should understand that they may not be able to assess their own driving competence and the degree of impairment caused by this drug; if they are unable to wait 8 hours or more before driving a motor vehicle or operating machinery, they should not take this medication.

Monitoring:

• Monitor for risk of drug abuse and signs of misuse or abuse
• Monitor heart rate in patients for whom changes in heart rate may be problematic
• Monitor blood pressure in patients for whom increased blood pressure not be tolerated

Patient advice:

• Patients should be instructed to read the US FDA-approved patient labeling (Patient Information and Instructions for Use).
• Patients should be instructed to avoid driving or operating machinery for at least 8 hours after taking a dose; if they are not able to wait the necessary time, they should not take a dose.

Frequently asked questions

• What are the new drugs for the treatment of migraines?

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer